AADI: Aadi Bioscience, Inc.
About
Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Los Angeles, CA.
Current Value
$2.301 Year Return
Current Value
$2.301 Year Return
Key Details
Market Cap
$56.20M
P/E Ratio
-1
1Y Stock Return
-52.00%
1Y Revenue Growth
7.80%
Dividend Yield
0.00%
Price to Book
0.8
Strategies that include AADI
Stock's related to AADI
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SEER | 34.48% | $140.34M | +45.12% | 0.00% |
| NRC | 29.32% | $456.84M | -53.38% | 2.45% |
| CRBU | 28.00% | $179.29M | -65.20% | 0.00% |
| DKL | 26.75% | $2.05B | -19.47% | 10.86% |
| TFC | 26.60% | $62.14B | +48.65% | 4.42% |
| TRUP | 26.58% | $2.23B | +99.73% | 0.00% |
| GOLF | 26.56% | $4.34B | +23.81% | 1.17% |
| IDA | 26.55% | $6.33B | +22.46% | 2.81% |
| ETR | 26.55% | $32.49B | +49.77% | 3.02% |
| DUK | 26.55% | $88.73B | +27.11% | 3.59% |
| PACB | 26.52% | $484.74M | -78.83% | 0.00% |
| TWST | 26.51% | $2.44B | +74.97% | 0.00% |
| CCI | 26.51% | $45.42B | +1.36% | 5.96% |
| BAC | 26.49% | $356.48B | +56.80% | 2.11% |
| MG | 26.48% | $12.68B | -18.79% | 4.30% |
| TROW | 26.47% | $26.25B | +20.89% | 4.18% |
| EDIT | 26.46% | $195.64M | -77.41% | 0.00% |
| HST | 26.43% | $12.51B | +4.17% | 4.46% |
| FIGS | 26.31% | $799.81M | -31.24% | 0.00% |
| KBH | 26.30% | $5.70B | +46.72% | 1.21% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| IMNN | -0.02% | $10.05M | -22.14% | 0.00% |
| BCSF | 0.07% | $1.07B | +10.80% | 10.10% |
| NFE | -0.08% | $2.39B | -74.26% | 3.14% |
| HUT | -0.09% | $2.20B | +143.32% | 0.00% |
| FTI | 0.12% | $12.77B | +43.50% | 0.66% |
| ANET | -0.12% | $127.54B | +86.03% | 0.00% |
| XGN | 0.15% | $69.14M | +151.28% | 0.00% |
| NSSC | 0.16% | $1.37B | +30.10% | 1.08% |
| HIHO | -0.18% | $8.50M | -1.53% | 6.22% |
| HUSA | 0.22% | $18.58M | -19.77% | 0.00% |
| BBIO | -0.24% | $4.39B | -21.22% | 0.00% |
| KD | -0.27% | $7.55B | +79.01% | 0.00% |
| TW | 0.29% | $28.79B | +42.00% | 0.29% |
| AVGO | -0.30% | $765.69B | +68.66% | 9.94% |
| FLG | 0.30% | $4.47B | -60.64% | 0.64% |
| TCOM | -0.35% | $41.98B | +86.57% | 0.00% |
| AVAV | 0.39% | $5.48B | +48.63% | 0.00% |
| INTA | 0.40% | $4.58B | +54.84% | 0.00% |
| LUMO | -0.40% | $37.45M | +40.58% | 0.00% |
| ELF | -0.41% | $6.90B | +7.66% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BVN | -35.79% | $3.12B | +34.06% | 0.00% |
| VRCA | -26.68% | $45.14M | -72.88% | 0.00% |
| SNCR | -20.04% | $96.79M | +74.10% | 0.00% |
| NAT | -18.71% | $624.30M | -32.35% | 14.12% |
| ASC | -15.26% | $497.50M | -11.99% | 9.03% |
| INSW | -14.76% | $2.03B | -1.61% | 1.17% |
| STNG | -14.67% | $2.81B | -6.67% | 2.97% |
| DHT | -14.59% | $1.67B | +1.17% | 7.78% |
| TKC | -14.52% | $5.96B | +38.82% | 1.32% |
| BAP | -14.15% | $15.80B | +58.12% | 4.67% |
| TNK | -13.68% | $1.44B | -17.00% | 2.40% |
| TEN | -13.50% | $594.24M | -2.47% | 4.52% |
| WHLM | -13.44% | $19.81M | -14.82% | 0.00% |
| DOCU | -13.34% | $16.27B | +89.66% | 0.00% |
| IMMP | -12.79% | $267.64M | -2.13% | 0.00% |
| FRO | -11.88% | $4.35B | -10.94% | 9.87% |
| OXBR | -11.19% | $19.24M | +183.49% | 0.00% |
| TRMD | -11.13% | $2.09B | -31.23% | 34.21% |
| LPG | -10.66% | $1.08B | -33.27% | 0.00% |
| NTIC | -10.15% | $134.44M | +28.17% | 1.97% |
ETF's related to AADI
News
Yahoo
As the U.S. stock market takes a breather after a significant post-election rally, investors are assessing their portfolios amid heightened optimism and fluctuating indices. In this context, penny stocks—often representing smaller or newer companies—remain an intriguing investment area despite their vintage name. These stocks can offer growth opportunities at lower price points when backed by solid financials, presenting potential for impressive returns without the typical risks associated...
Yahoo
Aadi Bioscience, Inc. (NASDAQ: AADI) today announced financial results for the third quarter ended September 30, 2024, and provided recent corporate progress.
Yahoo
Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it will halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. An analysis by the Independent Data Monitoring Committee demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval, the key goal of this Phase 2 study. The approximately 25 patients in PRECISION1 who are still benefiting from nab-sirol
SeekingAlpha
Aadi Bioscience, Inc. (NASDAQ:NASDAQ:AADI) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ETCompany ParticipantsDavid Lennon - President and Chief...
SeekingAlpha
The following slide deck was published by Aadi Bioscience, Inc.
Yahoo
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.